Chad Robins

As Chief Executive Officer and Co-Founder of Adaptive Biotechnologies, Chad Robins has led the company in building a proprietary immune medicine platform that fuels businesses across life sciences research, clinical diagnostics, and drug discovery. He guided Adaptive through its initial public offering, which was one of the year’s most successful biotech IPOs, and, under Chad’s leadership, Adaptive successfully launched the clinical diagnostic clonoSEQ®, the first and only FDA-authorized NGS-based test to detect and monitor minimal residual disease in certain B-cell cancers.

Chad has also propelled Adaptive into the burgeoning health tech space, forging a partnership with tech giant Microsoft, and bringing cloud computing and machine learning together with Adaptive’s technology to map the immune response of many diseases. This work fuels a pipeline of diagnostic tests across cancer, autoimmune disorders, and infectious disease. Most recently, the company launched T-Detect™ COVID, the first clinical T-cell based test for patients to confirm recent or past COVID-19 infection. Adaptive is also working to discover potent neutralizing antibodies to potentially prevent and treat COVID-19.

Chad is routinely recognized for excellence and innovation. In 2019 and 2020, he was included in the Puget Sound Business Journal’s Power 100, and Chad has been named a Goldman Sachs Most Intriguing Entrepreneur each year since 2015. He also received the 2016 Ernst & Young Entrepreneur of the Year® – The Pacific Northwest Region Award. Adaptive was awarded Seattle Business Magazine’s Leaders in Health Care 2020 – Achievement in Medical Technology, as well as the Deloitte Technology Fast 500 each year since 2016. In addition, under Chad’s leadership, Adaptive has consistently been voted Best Places to Work by the Puget Sound Business Journal.